Immunohistochemistry for alpha-synuclein showing positive staining (brown) of an intraneural Lewy-body in the Substantia nigra in Parkinson’s disease. A study published in February in the journal Scientific Reports suggests that doxycycline, an antibiotic used against bacterial infections for over a half-century, can be prescribed at lower doses for the treatment of Parkinson’s disease. According to the...
Tag: <span>Parkinson’s disease</span>
Post
Neuronal targets to restore movement in Parkinson’s disease model
Researchers working in the lab of Carnegie Mellon University neuroscientist Aryn Gittis, have identified two groups of neurons that can be turned on and off to alleviate the movement-related symptoms of Parkinson’s disease. The activation of these cells in the basal ganglia relieves symptoms for much longer than current therapies, like deep brain stimulation and...
Post
150-year-old drug may provide ‘off’ time relief for people with advanced Parkinson’s disease
Immunohistochemistry for alpha-synuclein showing positive staining (brown) of an intraneural Lewy-body in the Substantia nigra in Parkinson’s disease. New research provides evidence that an old drug may provide relief for people with advanced Parkinson’s, according to a study released today that will be presented at the American Academy of Neurology’s 69th Annual Meeting in...
Post
Pioneering research into benefit of computer games to treat Parkinson’s Disease
Left- right are: Dr Aaron Pritchard, (BCUHB – Research & Development), Dr Rudi Coetzer – Bangor/BCUHB Joint Appointment and Prof Charles Leek. North Wales neuroscientists are researching the potential benefits of brain stimulating computer games in the treatment of Parkinson’s Disease. The study is being led by researchers at Bangor University’s School of Psychology...
Post
Homing System Delivers Drugs To Specific Neurons
New technique reveals synaptic contributions to Parkinson’s Disease An artist’s rendition of how the new DART system works in a neural synaptic receptor. The red posts are the beacons that attract the white triangular ‘homing devices.’ This traps drugs (represented as hexagons) via a striped leash. Biomedical engineers have developed a way to deliver drugs...
Post
Your Brain Cells Could Be Reprogrammed to Fight Parkinson’s Disease
IN BRIEF Researchers have reprogrammed existing brain cells in mice into dopamine neurons to reduce their symptoms of Parkinson’s disease. This novel approach could be used to treat Parkinson’s disease with stem cells which are not transplanted, but induced from patients’ own brain cells. SUPPORT CELLS TURNED SUPER CELLS Parkinson’s disease is one of the...
Post
FDA approves drug to treat Parkinson’s disease
The U.S. Food and Drug Administration today approved Xadago (safinamide) tablets as an add-on treatment for patients with Parkinson’s disease who are currently taking levodopa/carbidopa and experiencing “off” episodes. An “off” episode is a time when a patient’s medications are not working well, causing an increase in Parkinson’s symptoms, such as tremor and difficulty walking....
Post
Scientific discovery may change treatment of Parkinson’s disease
When monitoring Parkinson’s disease, SPECT imaging of the brain is used for acquiring information on the dopamine activity. A new study conducted in Turku, Finland, shows that the dopamine activity observed in SPECT imaging does not reflect the number of dopamine neurons in the substantia nigra, as previously assumed. One of the most significant changes...
Post
Bowel cancer medication could help combat early-onset Parkinson’s disease
People with certain forms of early-onset Parkinson’s disease could potentially benefit from taking a medication used to treat certain forms of cancer, according to new research by University of Leicester scientists and funded by the Medical Research Council. The study, which has been published in Science Matters, suggests that folinic acid, which is used in medications...
Post
Extended Use of MAO-B Inhibitors Slows Decline in Parkinson’s Disease Patients
Amsterdam, NL, March 6, 2017 – There has long been interest in whether monoamine oxidase type B (MAO-B) inhibitors slow progression of Parkinson’s disease (PD) and improve long-term outcomes. They have shown neuroprotective effects in cell culture and animal studies of PD, but clinical trial results have been mixed and have failed to convincingly demonstrate...